Search

Author/Creator Rotolo, F.

2. LACUTAMAB IN PATIENTS (PTS) WITH ADVANCED MYCOSIS FUNGOIDES (MF) ACCORDING TO KIR3DL2 EXPRESSION: EARLY RESULTS FROM THE TELLOMAK PHASE 2 TRIAL. (17th June 2021)

Authors:
Bagot, M.; Kim, Y.; Zinzani, P. L.; Dalle, S.; Beylot‐barry, M.; Ortiz‐Romero, P. L; Cambalia, A.; Dereure, O.; Mortier, L.; Jacobsen, E.; Rotolo, F.; Azim, H. A; Porcu, P.
Journal:
Hematological oncology
Issue:
Volume 39(2021)Supplement 2
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort. (December 2018)

Authors:
Kandel, M.; Allayous, C.; Dalle, S.; Mortier, L.; Dalac, S.; Dutriaux, C.; Leccia, M.T.; Guillot, B.; Saiag, P.; Lacour, J.P.; Legoupil, D.; Lesimple, T.; Aubin, F.; Beylot-Barry, M.; Brunet-Possenti, F.; Arnault, J.P.; Granel-Brocard, F.; Stoebner, P.E.; Dupuy, A.; Maubec, E.
Journal:
European journal of cancer
Issue:
Volume 105(2018)
Page Start:
33
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗